233 related articles for article (PubMed ID: 29120910)
1. Biomarkers for immunotherapy in urological cancers.
Gust KM; Resch I; D'Andrea D
Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials.
Hsu MM; Balar AV
Clin Genitourin Cancer; 2019 Jun; 17(3):e618-e626. PubMed ID: 31005473
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors in renal cell carcinoma.
Ross K; Jones RJ
Clin Sci (Lond); 2017 Nov; 131(21):2627-2642. PubMed ID: 29079639
[TBL] [Abstract][Full Text] [Related]
4. Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?
Sabanathan D; Park JJ; Marquez M; Francisco L; Byrne N; Gurney H
Oncologist; 2017 Dec; 22(12):1470-1477. PubMed ID: 29146617
[TBL] [Abstract][Full Text] [Related]
5. Signification of protein p-53 isoforms and immune therapeutic success in chronic lymphocytic leukemia.
Udristioiu A; Nica-Badea D
Biomed Pharmacother; 2018 Oct; 106():50-53. PubMed ID: 29945117
[TBL] [Abstract][Full Text] [Related]
6. Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review.
Haibe Y; El Husseini Z; El Sayed R; Shamseddine A
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867025
[TBL] [Abstract][Full Text] [Related]
7. Novel therapies in urothelial carcinoma: a biomarker-driven approach.
Iyer G; Rosenberg JE
Ann Oncol; 2018 Dec; 29(12):2302-2312. PubMed ID: 30016395
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on the clinical development of immunotherapy in prostate cancer.
Cordes LM; Gulley JL; Madan RA
Asian J Androl; 2018; 20(3):253-259. PubMed ID: 29582792
[TBL] [Abstract][Full Text] [Related]
9. Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma.
Kurtoglu M; Davarpanah NN; Qin R; Powles T; Rosenberg JE; Apolo AB
Clin Genitourin Cancer; 2015 Oct; 13(5):410-20. PubMed ID: 25862322
[TBL] [Abstract][Full Text] [Related]
10. The co-expression of antigen targets as a rationale for ADC combination in urothelial cancer.
Bertucci F; de Nonneville A; Finetti P; Cohendet A; Guille A; Mamessier E
Ann Oncol; 2024 May; 35(5):477-478. PubMed ID: 38364991
[No Abstract] [Full Text] [Related]
11. Evolving adoptive cellular therapies in urological malignancies.
Wong YNS; Joshi K; Pule M; Peggs KS; Swanton C; Quezada SA; Linch M
Lancet Oncol; 2017 Jun; 18(6):e341-e353. PubMed ID: 28593860
[TBL] [Abstract][Full Text] [Related]
12. Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers.
Mock A; Zschäbitz S; Kirsten R; Scheffler M; Wolf B; Herold-Mende C; Kramer R; Busch E; Jenzer M; Jäger D; Grüllich C
Cancer Immunol Immunother; 2019 Dec; 68(12):2005-2014. PubMed ID: 31701161
[TBL] [Abstract][Full Text] [Related]
13. Complications of immuno-oncology care: what urologist should know.
Grajales V; Martini A; Shore ND
BJU Int; 2024 May; 133(5):524-531. PubMed ID: 38437876
[TBL] [Abstract][Full Text] [Related]
14. Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?
Sonpavde G; Bellmunt J
Oncologist; 2015 May; 20(5):461-3. PubMed ID: 25845991
[TBL] [Abstract][Full Text] [Related]
15. 4th Symposium on Advances in Cancer Immunology and Immunotherapy, November 29-December 1, 2018, Athens, Greece.
Fortis SP; Kotsakis A; Le Tourneau C; Tsitsilonis OE; Georgoulias V; Baxevanis CN
Cancer Immunol Immunother; 2019 Aug; 68(8):1391-1400. PubMed ID: 31309256
[No Abstract] [Full Text] [Related]
16. Established and emerging biomarkers of immunotherapy in renal cell carcinoma.
Jani Y; Jansen CS; Gerke MB; Bilen MA
Immunotherapy; 2024 Apr; 16(6):405-426. PubMed ID: 38264827
[TBL] [Abstract][Full Text] [Related]
17. Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies.
Jesus VHF; Felismino TC; Barros E Silva MJ; Souza E Silva V; Riechelmann RP
Clinics (Sao Paulo); 2018 Oct; 73(suppl 1):e510s. PubMed ID: 30365605
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint targeting as anti-cancer immunotherapy: promises, questions, challenges and the need for predictive biomarkers at ASCO 2015.
Pandha H; Pawelec G
Cancer Immunol Immunother; 2015 Sep; 64(9):1071-4. PubMed ID: 26267043
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in Gastrointestinal Cancers.
Procaccio L; Schirripa M; Fassan M; Vecchione L; Bergamo F; Prete AA; Intini R; Manai C; Dadduzio V; Boscolo A; Zagonel V; Lonardi S
Biomed Res Int; 2017; 2017():4346576. PubMed ID: 28758114
[TBL] [Abstract][Full Text] [Related]
20. CanImmunother: a manually curated database for identification of cancer immunotherapies associating with biomarkers, targets, and clinical effects.
Zhang W; Zeng B; Lin H; Guan W; Mo J; Wu S; Wei Y; Zhang Q; Yu D; Li W; Chan GC
Oncoimmunology; 2021; 10(1):1944553. PubMed ID: 34345532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
